Reproductive Genetics Market Report 2026

The reproductive genetics market size has grown rapidly in recent years. It will grow from $7.91 billion in 2025 to $9.15 billion in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to growth in assisted reproductive technologies usage, increasing maternal age at conception, expansion of fertility clinics, rising awareness of inherited genetic disorders, availability of advanced molecular diagnostic tools.

The reproductive genetics market size is expected to see rapid growth in the next few years. It will grow to $16.22 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to growing adoption of precision reproductive medicine, rising investments in fertility genomics research, expansion of non-invasive prenatal testing, increasing use of ai-driven genetic interpretation, advancements in sequencing accuracy and affordability. Major trends in the forecast period include increasing adoption of preimplantation genetic testing, rising demand for carrier screening solutions, growing use of ngs-based reproductive diagnostics, expansion of personalized fertility treatment planning, enhanced integration of laboratory automation.

The rising prevalence of genetic disorders is expected to drive growth in the reproductive genetics market in the coming years. Genetic disorders are diseases caused by abnormalities in an individual’s DNA, ranging from single-gene mutations to chromosomal defects. The increasing focus on reproductive genetic testing allows families to gain early insights, reduce uncertainty, make informed reproductive decisions, and help prevent the transmission of inherited conditions. Reproductive genetics plays a vital role in detecting and managing genetic disorders, supporting families in making informed choices, and reducing the risk of passing conditions to future generations. For example, in July 2024, Cystic Fibrosis Australia, a national consumer body, reported that the number of individuals with Cystic Fibrosis in the Australian Cystic Fibrosis Data Registry (ACFDR) increased from 3,738 in 2022 to 3,798 in 2023, representing a 1.6% rise. Therefore, the growing prevalence of genetic disorders is expected to propel the expansion of the reproductive genetics market.

Key companies in the reproductive genetics market are focusing on technological innovations, such as comprehensive multi-trait embryo comparison, to enable more precise, data-driven, and personalized embryo selection for IVF patients. Comprehensive multi-trait embryo comparison evaluates multiple embryos simultaneously across hundreds of hereditary conditions and complex traits using genomic and polygenic scoring, allowing prospective parents to make more informed decisions during in vitro fertilization. For instance, in June 2025, Nucleus Genomics Inc., a U.S.-based biotechnology company, launched Nucleus Embryo, a reproductive genetics platform that allows patients to analyze and compare up to 20 embryos across more than 900 inherited conditions. The platform incorporates polygenic scoring for complex traits such as appearance, cognitive ability, and mental health, offering a comprehensive multi-trait comparison interface that significantly expands embryo-selection capabilities beyond traditional screening methods.

In January 2024, Natera Inc., a U.S.-based genetic testing and diagnostics company, acquired health assets from Invitae Corporation for $52.5 million. Through this acquisition, Natera aims to expand its reproductive genetics services by integrating Invitae’s non-invasive prenatal screening and carrier screening business to better serve patients and healthcare providers. Invitae Corporation, based in the U.S., provides reproductive genetics services, including preimplantation genetic testing, carrier screening, and miscarriage analysis.

Major companies operating in the reproductive genetics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Revvity Inc., Medicover AB, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., The Cooper Companies Inc., Vitrolife AB, BillionToOne Inc., Sophia Genetics SA, Eurofins Genomics India Private Limited, Invitae Corporation, Igenomix, Gonagen GmbH, Darwin AG.

North America was the largest region in the reproductive genetics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the reproductive genetics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the reproductive genetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the reproductive genetics market by increasing costs of imported sequencing platforms, reagents, laboratory consumables, and bioinformatics infrastructure. Diagnostic laboratories and fertility clinics in North America and Europe are most impacted due to dependence on imported NGS systems, while Asia-Pacific faces higher costs for expanding genetic testing capacity. These tariffs are raising testing prices and slowing laboratory expansion. At the same time, they are promoting regional manufacturing of reagents, localized test development, and domestic innovation in reproductive genetic diagnostics.

The reproductive genetics market research report is one of a series of new reports that provides reproductive genetics market statistics, including reproductive genetics industry global market size, regional shares, competitors with a reproductive genetics market share, detailed reproductive genetics market segments, market trends and opportunities, and any further data you may need to thrive in the reproductive genetics industry. This reproductive genetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Reproductive genetics is a branch of genetics that examines how genetic factors influence reproduction and the inheritance of traits. It focuses on the genetic composition of individuals involved in reproduction, studying how genes and chromosomes affect fertility, conception, and embryo development. This field investigates the impact of inherited genetic variations on reproductive health, aiming to improve understanding of the biological processes underlying human reproduction and heredity.

The main product types in reproductive genetics include kits, laboratory-developed tests (LDTs), and reagents and consumables. Kits refer to the offspring produced from a single reproductive event and are often used to describe litters in animals such as rabbits or ferrets. Technologies employed include polymerase chain reaction (PCR), next-generation sequencing (NGS), in-situ hybridization (ISH), and microarray analysis, applied for detecting aneuploidy, single-gene disorders, structural chromosomal abnormalities, and more. These products are used by hospitals, diagnostic laboratories, fertility clinics, and research institutions.

The reproductive genetics market consists of revenues earned by entities by providing services such as infertility genetic testing, genetic counselling, genomic data interpretation, and risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The reproductive genetics market also includes sales of cryopreservation media, embryo biopsy tools, and lab information management systems (LIMS). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.